For the quarter, revenues were $41,951, compared to $828,673 for the same
period in 2006. During this quarter, ART sold only Fenestra products; there
were no eXplore Optix units sold during that period. The company is developing a
new sales distribution model for eXplore Optix with GE Healthcare.
Net loss for the second quarter was $3,170,391, compared to $3,643,064 for
the same period in 2006. The company's cash position is
$4.3 million, with working capital of about $5 million.
In clinical news, ART presented the preliminary results of a pilot study
being conducted at Sunnybrook Health Sciences Centre in Toronto, showing that
SoftScan could be effective at showing earlier evidence of therapeutic response
to breast cancer treatment. The company has also signed an agreement with
Stanford University to conduct clinical research on SoftScan's effectiveness.
By AuntMinnie.com staff writers
facility to evaluate ART's SoftScan, July 13, 2007
August 16, 2007
debuts new optical molecular imaging unit, May 17, 2007
revenues slip in 2006, March 26, 2007
lands CE Mark, February 8, 2007
GE extend eXplore Optix pact, December 22, 2006
gets Health Canada approval for SoftScan, December 14, 2006
Copyright © 2007 AuntMinnie.com